No, Entresto (sacubitril/valsartan) is NOT indicated for Stage B heart failure
Stage B heart failure patients (asymptomatic LV systolic dysfunction) should be treated with ACE inhibitors and beta-blockers, NOT Entresto. Entresto is specifically indicated only for symptomatic heart failure patients (NYHA Class II-IV) with reduced ejection fraction.
Why Entresto is Not Appropriate for Stage B HF
Guideline-Directed Therapy for Stage B HF
The established treatment for Stage B heart failure (structural heart disease without symptoms) is clear and evidence-based 1:
- ACE inhibitors are Class I, Level A recommendation for patients with asymptomatic LV systolic dysfunction and history of MI to prevent or delay onset of symptomatic HF and prolong life
- Beta-blockers are Class I, Level B recommendation for the same population
Entresto's Specific Indication
Entresto is exclusively indicated for symptomatic heart failure patients 1, 2, 3, 4:
- The FDA label and all major guidelines specify use in NYHA Class II-IV (symptomatic) patients 5
- The PARADIGM-HF trial, which established Entresto's efficacy, enrolled only symptomatic patients: 70% NYHA Class II, 24% Class III, and 0.7% Class IV 5
- Patients were required to tolerate ACE inhibitor therapy before randomization
The 2017 ACC/AHA guideline explicitly states: "In patients with chronic symptomatic HFrEF NYHA class II or III who tolerate an ACE inhibitor or ARB, replacement by an ARNI is recommended" 2. Note the word "symptomatic."
The Correct Treatment Algorithm for Stage B HF
First-Line Therapy
- Start ACE inhibitor at low dose, titrate to target doses shown in clinical trials
- Add beta-blocker (carvedilol, metoprolol succinate, or bisoprolol)
- Treat hypertension aggressively (Class I, Level A) 1
When to Consider Entresto
Only after the patient develops symptoms (transitions to Stage C/NYHA Class II or higher):
- Patient must first tolerate ACE inhibitor or ARB therapy
- Must have LVEF ≤40% (or ≤35% per some guidelines)
- Should have elevated natriuretic peptides (BNP >150 pg/mL or NT-proBNP ≥600 pg/mL, or lower thresholds with recent hospitalization) 2
Critical Pitfalls to Avoid
Do not jump to Entresto in asymptomatic patients simply because it showed superior outcomes in PARADIGM-HF. The trial specifically excluded asymptomatic patients, and there is no evidence base for its use in Stage B HF. The established mortality benefit of ACE inhibitors in asymptomatic LV dysfunction comes from different trials (SAVE, SOLVD) that did not include Entresto 6.
The run-in design of PARADIGM-HF is crucial to understand 5: Patients had to tolerate enalapril 10 mg twice daily, then Entresto 100 mg twice daily, before randomization. This means 20.9% of screened patients were discontinued during run-in periods, primarily due to hypotension, renal dysfunction, and hyperkalemia. Stage B patients have not been tested for this tolerability.
Bottom Line
Stage B heart failure requires ACE inhibitors and beta-blockers as foundational therapy 1. Entresto should only be considered after patients develop symptoms and have demonstrated tolerance to ACE inhibitor or ARB therapy 2, 3, 4. Using Entresto in asymptomatic patients would be off-label, unsupported by evidence, and potentially expose patients to unnecessary risks (hypotension, renal dysfunction, hyperkalemia, angioedema) without proven benefit 5.